Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.40 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.37 |
| ▸ | NSD2 | O96028 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29903147 | 1.00 | ALDH1A1 (0.40) | ALDH1A1MEN1KMT2ADNMT1CACNA1B | |
| SCHEMBL31049123 | 0.85 | NQO2 (0.47) | ALDH1A1MEN1KMT2ADNMT1CACNA1B | |
| SCHEMBL9234732 | 0.85 | MEN1 (0.54) | ALDH1A1MEN1KMT2ADNMT1CACNA1B | |
| SCHEMBL25323401 | 0.83 | HSD17B10 (0.39) | ALDH1A1MEN1KMT2ADNMT1CACNA1B | |
| SCHEMBL25352843 | 0.82 | MEN1 (0.41) | ALDH1A1MEN1KMT2ADNMT1CACNA1B | |
| SCHEMBL23053933 | 0.82 | ESR1 (0.39) | ALDH1A1MEN1KMT2ADNMT1CACNA1B | |
| SCHEMBL22208228 | 0.82 | MEN1 (0.39) | ALDH1A1MEN1KMT2ADNMT1CACNA1B | |
| SCHEMBL25308480 | 0.82 | MEN1 (0.41) | ALDH1A1MEN1KMT2ADNMT1CACNA1B | |
| SCHEMBL29418778 | 0.82 | MEN1 (0.39) | ALDH1A1MEN1KMT2ADNMT1CACNA1B | |
| SCHEMBL26708991 | 0.82 | ALDH1A1 (0.36) | ALDH1A1MEN1KMT2ADNMT1CACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051361-A1 | 5,6,7,8-TETRAHYDRO-2,6-NAPHTHYRIDINE DERIVATIVES AS CANCER THERAPEUTICS | VRISE THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| US-20240317759-A1 | SMALL MOLECULE INHIBITORS OF KRAS MUTATED PROTEINS | TAIHO PHARMACEUTICAL CO LTD (JP) | 2024-09-26 | — | — | US | disclosed |
| EP-4347041-A1 | SMALL MOLECULE INHIBITORS OF KRAS MUTATED PROTEINS | Taiho Pharmaceutical Co., Ltd. (JP) | 2024-04-10 | — | — | EP | disclosed |
| CN-117769554-A | Small molecule inhibitors of KRAS muteins | 大鹏药品工业株式会社 | 2024-03-26 | — | — | CN | disclosed |
| US-20230348495-A1 | A COMPOUND HAVING INHIBITORY ACTIVITY AGAINST KRAS G12D MUTATION | ASTEX THERAPEUTICS LIMITED (GB) | 2023-11-02 | — | — | US | disclosed |
| CN-116801883-A | Heteroaromatic ring compounds, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-09-22 | — | — | CN | disclosed |
| WO-2023125627-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | LYNK PHARMACEUTICALS CO., LTD. (CN) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023105491-A1 | 5,6,7,8-TETRAHYDRO-2,6-NAPHTHYRIDINE DERIVATIVES AS CANCER THERAPEUTICS | VRISE THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| CN-115850267-A | Bridged ring compound, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-03-28 | — | — | CN | disclosed |
| WO-2022250170-A9 | SMALL MOLECULE INHIBITORS OF KRAS MUTATED PROTEINS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-01-05 | — | — | WO | disclosed |
| WO-2022250170-A1 | SMALL MOLECULE INHIBITORS OF KRAS MUTATED PROTEINS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2022-12-01 | — | — | WO | disclosed |
| EP-4065583-A1 | A COMPOUND HAVING INHIBITORY ACTIVITY AGAINST KRAS G12D MUTATION | Taiho Pharmaceutical Co., Ltd. (JP) | 2022-10-05 | — | — | EP | disclosed |
| WO-2022194192-A1 | HETEROAROMATIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2022-09-22 | — | — | WO | disclosed |
| WO-2022194192-A1 | HETEROAROMATIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2022-09-22 | — | — | WO | disclosed |
| CN-115003677-A | Compounds having inhibitory activity against KRAS G12D mutation | 大鹏药品工业株式会社 | 2022-09-02 | — | — | CN | disclosed |
| WO-2021107160-A1 | A COMPOUND HAVING INHIBITORY ACTIVITY AGAINST KRAS G12D MUTATION | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021106231-A1 | A COMPOUND HAVING INHIBITORY ACTIVITY AGAINST KRAS G12D MUTATION | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317759-A1 | SMALL MOLECULE INHIBITORS OF KRAS MUTATED PROTEINS | KRAS, NRAS, HRAS | ALDH1A1 2535/4885MEN1 290/4885KMT2A 1975/4885 |
| US-20230348495-A1 | A COMPOUND HAVING INHIBITORY ACTIVITY AGAINST KRAS G12D MUTATION | KRAS, NRAS, HRAS | ALDH1A1 2932/4885MEN1 275/4885KMT2A 1326/4885 |
| US-20250051361-A1 | 5,6,7,8-TETRAHYDRO-2,6-NAPHTHYRIDINE DERIVATIVES AS CANCER THERAPEUTICS | KRAS, NRAS, TP53 | ALDH1A1 2082/4885MEN1 1064/4885KMT2A 2720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.